POS0379 WHEN SHOULD WE USE MARGINAL STRUCTURAL MODELS FOR DRUG STUDIES IN RHEUMATOLOGY? THE EXAMPLE OF CORTICOSTEROIDS AND INFECTIONS IN RHEUMATOID ARTHRITIS

Abstract

BackgroundThe use and dosing of pharmacotherapy for chronic inflammatory disease is commonly changed over time, adapting to previous treatment response, current disease activity, tolerability, and onset of adverse events. This...